CompletedNCT03787628
Cannabidiol Added to Buprenorphine for Opioid Use Disorder
About this title
Read the official source — NCT03787628Medication studyAges 18+United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- TarzanaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 19, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 35
- Sponsor
- University of California, Los Angeles
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03787628
- Official title
Show the full official title
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tarzana
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, Los Angeles, a university.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol (CBD) 600 mg and Placebo.
Who was this study for?
Listed age limits: from 18 years.
